Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

Onno C. P. van Schayck*, John Haughney, Michel Aubier, Olof Selroos, Tommy Ekstrom, Juliette Ostinelli, Roland Buhl

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

18 Citations (Web of Science)


Background: Studies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics. Methods: EuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort (R) Turbuhaler (R))(h) maintenance and reliever therapy (Symbicort SMART (R)) at two maintenance doses of budesonide/formoterol (160/4.5 mu g), 1 x 2 and 2 x 2, in patients with asthma who were symptomatic despite treatment with ICS +/- long-acting beta(2)-agonists. The 8424 randomised patients included 886 smokers (11%; aged
Original languageEnglish
Pages (from-to)189-196
JournalRespiratory Medicine
Issue number2
Publication statusPublished - Feb 2012


  • ACQ-5
  • Asthma
  • Budesonide/formoterol maintenance and reliever therapy
  • Propensity-matched controls
  • Smokers
  • Symbicort SMART

Cite this